Prospective study on cervical neoplasia IV. Presence of HPV antibodies
Jazyk angličtina Země Spojené státy americké Médium print
Typ dokumentu časopisecké články, práce podpořená grantem
PubMed
9935175
DOI
10.1002/(sici)1097-0215(19990129)80:3<365::aid-ijc5>3.0.co;2-c
PII: 10.1002/(SICI)1097-0215(19990129)80:3<365::AID-IJC5>3.0.CO;2-C
Knihovny.cz E-zdroje
- MeSH
- biologické markery krev MeSH
- DNA vazebné proteiny * MeSH
- dospělí MeSH
- lidé středního věku MeSH
- lidé MeSH
- nádory děložního čípku imunologie virologie MeSH
- onkogenní proteiny virové krev MeSH
- Papillomaviridae imunologie MeSH
- Papillomavirus E7 - proteiny MeSH
- prospektivní studie MeSH
- protilátky virové krev MeSH
- Check Tag
- dospělí MeSH
- lidé středního věku MeSH
- lidé MeSH
- ženské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
- práce podpořená grantem MeSH
- Názvy látek
- biologické markery MeSH
- DNA vazebné proteiny * MeSH
- E2 protein, Human papillomavirus type 16 MeSH Prohlížeč
- oncogene protein E4, Human papillomavirus type 16 MeSH Prohlížeč
- oncogene protein E7, Human papillomavirus type 16 MeSH Prohlížeč
- onkogenní proteiny virové MeSH
- Papillomavirus E7 - proteiny MeSH
- protilátky virové MeSH
Sera collected in the course of a prospective study carried out in Prague in 1975-1983 were assayed for the presence of human papillomavirus (HPV) antibodies. Women with cervical neoplasia proven by biopsy at enrollment possessed antibodies to peptides derived from E2, E4 and E7 proteins of HPV16 and to virus-like particles (VLPs) of HPV16, -18 and -33 significantly more frequently than matched controls. Women without cervical neoplasia at enrollment who developed the disease in the course of the study differed from matched controls by a higher prevalence of antibodies against VLPs of HPV16 and -18 but not against early antigens of HPV16. In 19 of the latter subjects, paired serum specimens were tested, the first samples having been taken at enrollment and the second at diagnosis. Development of the disease was associated with seroconversion from negativity to positivity to at least one HPV antigen in 11 (57.9%) women.
Citace poskytuje Crossref.org